Transgene S.a.

Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts

Transgene

Karola Rittner

Christine Thioudellet

Nathalie Silvestre

Jean-Baptiste Marchand

Michel Geist

Majid Mehtali

Monika Lusky

Jürgen Kleinschmidt

Dirk Grimm

Xavier Preville

Christelle Remy

Philippe Slos

Julie Hortelano

The present invention is in the field of viral immunotherapy. The invention provides new pseudocowpox (PCPV) viruses, in particular recombinant PCPV, composition thereof as well as their therapeutic use for preventing or treating diseases, and, notably, proliferative diseases like cancers and restenosis and infectious diseases such as chronic ones. The present invention also provides methods for generating and amplifying such a PCPV and a method for eliciting or stimulating and/or re-orienting an immune response using such a PCPV. More specifically, the invention provides an alternative to the existing poxvirus vectors such as MVA (Modified Virus Ankara) and may be largely used for the therapeutic vaccination.

Recombinant pseudocowpoxvirus

The present invention provides an oncolytic virus comprising nucleotide sequence(s) encoding one or more immune checkpoint modulator(s). It also concerns a pharmaceutical composition comprising effective amount of said oncolytic virus and, eventually, a pharmaceutically acceptable vehicle and its use for treating proliferative diseases such as cancers.

Oncolytic virus for expression of immune checkpoint modulators

The present invention relates to an AAV DNA having helper virus sequences which are necessary for developing AAV viral particles, a system containing such a DNA and the use of both.

AAV DNA comprising helper virus sequences

Novel viral vectors in which the expression of viral genes is regulated in such a way that it is functional in a complementation cell and non-functional in a host cell, as well as viral particles and host cells containing said novel vectors, are disclosed. A complementation cell including a viral gene expression regulator, and a method for preparing infectious viral particles, are also disclosed. Finally, a pharmaceutical composition containing said vectors, and the therapeutical use thereof, are disclosed.

Viral vectors and line for gene therapy

Growing community of inventors

Strasbourg, France

Karola Rittner